Literature DB >> 24122012

3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis.

Bao-qin Cai1, Hai-xiao Jin1, Xiao-jun Yan1, Peng Zhu1, Gui-xiang Hu2.   

Abstract

AIM: To investigate the structural basis underlying potency and selectivity of a series of novel analogues of thieno[2,3-d]pyrimidin-4-yl hydrazones as cyclin-dependent kinase 4 (CDK4) inhibitors and to use this information for drug design strategies.
METHODS: Three-dimensional quantitative structure-activity relationship (3D-QSAR) and three-dimensional quantitative structure-selectivity relationship (3D-QSSR) models using comparative molecular field analysis (CoMFA) were conducted on a training set of 48 compounds. Partial least squares (PLS) analysis was employed. External validation was performed with a test set of 9 compounds.
RESULTS: The obtained 3D-QSAR model (q(2)=0.724, r(2)=0.965, r(2)pred=0.945) and 3D-QSSR model (q(2)=0.742, r(2)=0.923, r(2)pred=0.863) were robust and predictive. Contour maps with good compatibility to active binding sites provided insight into the potentially important structural features required to enhance activity and selectivity. The contour maps indicated that bulky groups at R1 position could potentially enhance CDK4 inhibitory activity, whereas bulky groups at R3 position have the opposite effect. Appropriate incorporation of bulky electropositive groups at R4 position is favorable and could improve both potency and selectivity to CDK4.
CONCLUSION: These two models provide useful information to guide drug design strategies aimed at obtaining potent and selective CDK4 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24122012      PMCID: PMC4075745          DOI: 10.1038/aps.2013.105

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  18 in total

1.  Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.

Authors:  Campbell McInnes; Shudong Wang; Sian Anderson; Janice O'Boyle; Wayne Jackson; George Kontopidis; Christopher Meades; Mokdad Mezna; Mark Thomas; Gavin Wood; David P Lane; Peter M Fischer
Journal:  Chem Biol       Date:  2004-04

2.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Authors:  R D Cramer; D E Patterson; J D Bunce
Journal:  J Am Chem Soc       Date:  1988-08-01       Impact factor: 15.419

3.  Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Cancer Cell       Date:  2006-01       Impact factor: 31.743

Review 4.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

5.  Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

Authors:  M Barvian; D H Boschelli; J Cossrow; E Dobrusin; A Fattaey; A Fritsch; D Fry; P Harvey; P Keller; M Garrett; F La; W Leopold; D McNamara; M Quin; S Trumpp-Kallmeyer; P Toogood; Z Wu; E Zhang
Journal:  J Med Chem       Date:  2000-11-30       Impact factor: 7.446

6.  A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.

Authors:  T Honma; T Yoshizumi; N Hashimoto; K Hayashi; N Kawanishi; K Fukasawa; T Takaki; C Ikeura; M Ikuta; I Suzuki-Takahashi; T Hayama; S Nishimura; H Morishima
Journal:  J Med Chem       Date:  2001-12-20       Impact factor: 7.446

7.  Discovery of novel Thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure-activity relationships.

Authors:  Takao Horiuchi; Yasuyuki Takeda; Noriyasu Haginoya; Masaki Miyazaki; Motoko Nagata; Mayumi Kitagawa; Kouichi Akahane; Kouichi Uoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  2011       Impact factor: 1.645

Review 8.  Role of the p16 tumor suppressor gene in cancer.

Authors:  W H Liggett; D Sidransky
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

9.  Cyclin-dependent kinases: a family portrait.

Authors:  Marcos Malumbres; Edward Harlow; Tim Hunt; Tony Hunter; Jill M Lahti; Gerard Manning; David O Morgan; Li-Huei Tsai; Debra J Wolgemuth
Journal:  Nat Cell Biol       Date:  2009-11       Impact factor: 28.824

10.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

View more
  4 in total

1.  Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches.

Authors:  Xiaojiao Luo; Yu Zhao; Pan Tang; Xingkai Du; Feng Li; Qingying Wang; Rong Li; Jun He
Journal:  Mol Divers       Date:  2020-08-08       Impact factor: 2.943

2.  Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR.

Authors:  Rui Li; Yongli Du; Zhipei Gao; Jingkang Shen
Journal:  Int J Mol Sci       Date:  2018-04-19       Impact factor: 5.923

3.  Machine learning vs. field 3D-QSAR models for serotonin 2A receptor psychoactive substances identification.

Authors:  Giuseppe Floresta; Vincenzo Abbate
Journal:  RSC Adv       Date:  2021-04-20       Impact factor: 3.361

4.  Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.

Authors:  Giuseppe Floresta; Orapan Apirakkan; Antonio Rescifina; Vincenzo Abbate
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.